leadf
logo-loader
ASX:OCC

Orthocell Ltd

Receive alerts
Market:
ASX
Market Cap:
$93.62 m
Price
0.51 AUD
Change
-0.98%
52 weeks high
0.65
52 weeks low
0.18

Orthocell Ltd is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects.

Products

Regenerative medicine seeks to use the body’s own ability for self-repair to replace injured or diseased tissue. Regenerative medicine treatments use biological substitutes to restore or improve tissue function. The “biological substitute” is either 

  • cell-based, where healthy cells are injected into diseased or damaged tissue to repair the damage
  • a resorbable implanted scaffold that encourages new tissue formation using the body’s own intrinsic repair processes
  • a combination of cells and scaffold, where cells are implanted into the repair site after seeding onto a scaffold. 

The potential of regenerative medicine to help maintain health and vitality as we age is enormous. Orthocell is committed to bringing the benefits of regenerative medicine to a broad patient population through the development of world-leading regenerative medicine therapies. Orthocell manufactures both cell therapies for cartilage and tendon repair and the CelGro™ collagen scaffold.

(click here for more information on products)


Last updated 6th April 2020

Paul Anderson
Managing Director

Paul has over 20 years’ experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product, rebating pathways, marketing, sales, developing key option leader relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.


Dr Stewart James Washer,
Chairman

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently the Chairman of Cynata Therapeutics Ltd (ASX:CYP) who are developing stem cell therapies, Chairman of Minomic International Ltd who have an accurate non-invasive test for prostate cancer and Investment Director with Bioscience Managers.

Previously Stewart was the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and the CEO of Celentis where he managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 scientists and $130m revenues. Stewart was Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University.


Matt Callahan
Corporate Adviser

Mr Callahan is an experienced life sciences executive based in Philadelphia.  He is the founding CEO of iCeutica Inc and a co-inventor of some of the technologies that comprise the SoluMatrix Fine Particle Technology™ platform that iCeutica uses to develop new pharmaceuticals.  iCeutica has developed two products to date that have received FDA approval, has 1 pending approval and 2 products in late stage development. He has more than 18 years legal, IP and investment management experience and is also a director of Glycan Bioscience LLC and founding CEO of Churchill Pharma.

Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors and was General Manager and General Counsel with Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.


Professor Lars Lidgren
Board Member

M.D., Ph.D. Professor in Orthopedics at the University Hospital of Lund. Professor Lidgren leads a productive regenerative medicine research group at the University Hospital of Lund. The hospital is a member of the ISOC group of worldwide leading hospitals and Professor Lidgren is an honorary member and past president of several major societies. He initiated the worldwide Bone and Joint Decade 2000-2010 and is a successful serial entrepreneur who founded the companies Scandimed (Biomet), Bone Support, AMeC and GWS in Sweden.


Mr Qi Xiao Zhou
Board Member

Mr Zhou has 15 years’ experience within China as a senior business manager and executive. He has been General Manager of Shenzhen Lightning Digital Technology Co Ltd since 2001, focused on the manufacture and distribution of Semiconductor/Integrated Circuit technology.

Mr Zhou has experience within the public markets in Hong Kong, China and Taiwan and brings to the Board a wealth of business management and business development experience within the Asian regions. In particular Mr Zhou has broad connections and experience in the licensing of technologies into China and licensing into the Asian region.


Last updated 6th April 2020

ORTHOCELL LTD

BUILDING 191 MURDOCH UNIVERSITY
SOUTH STREET MURDOCH WA
AUSTRALIA

Orthocell Ltd

Building 191 Murdoch University
South Street Murdoch WA 6150

ABN: 57 118 897 135

Monday – Friday: 9AM – 6PM
Saturday: Closed
Sunday: Closed


GENERAL, INVESTOR & ACCOUNT ENQUIRIES

P: +61 8 9360 2888
F: +61 8 9360 2899
E: general@orthocell.com.au


MEDIA ENQUIRIES

Haley Chartres
H^CK Director

P: +61 423 139 163
E: haley@hck.digital


SHARE REGISTRY

Automic Registry Services

PO Box 223
West Perth WA 6872
Australia

P: +61 8 9324 2099
W: www.automic.com.au
E: info@automic.com.au


Last updated 6th April 2020